Stimolazione cerebrale ultrasonica personalizzata per la depressione (R61)
Stimolazione cerebrale ultrasonica personalizzata per la depressione: uno studio sull'impegno bersaglio e gli effetti dell'umore
This study will evaluate a new form of non-invasive brain stimulation for individuals with depression. Personalized low-intensity transcranial focused ultrasound stimulation will be delivered using a range of stimulation parameters during psychological and physiological monitoring. Individualized optimal targets will be selected using structural MRI and diffusion tractography. Brain target engagement will be evaluated using functional MRI.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
This R61 project has 3 aims:
- To determine whether stimulation engages the subcallosal cingulate (SCC) in an intensity-dependent manner
- To examine the degree of specificity of neuromodulation by contrasting the neural effects of stimulating two spatially distinct targets versus sham
- To evaluate safety, tolerability, and side effects
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84108
- University of Utah
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Age 18-65, any gender.
- Primary diagnosis of DMS-5 major depressive disorder (MINI).
- Current moderate-to-severe depressive episode, without psychotic features, lasting at least 2 months (MINI).
- Self-rated 16-item Quick Inventory of Depressive Symptomatology (QIDS) total score > 10.
- History of at least 2 failed trials of evidence-based antidepressant medication and/or psychotherapy (at least one trial during the current depressive episode).
- Stated willingness to comply with all study procedures and avoid changes to psychiatric treatments (medications, psychotherapy) for the duration of the study.
- For participants of reproductive potential: negative pregnancy test or use of highly effective contraception for at least 1 month prior to baseline; agreement to use such a method throughout the study.
- Capacity to provide informed consent; provision of a signed and dated consent form
- Currently are under the care of a licensed psychiatrist or other mental health care provider, or a licensed addiction medicine specialist and agrees to promptly inform the investigator or the study staff of any change in these providers.
- Agrees to allow any and all forms of communication between the investigators/study staff and any healthcare provider who currently provides and/or has provided service to the patient/subject within at least two years of study enrollment for the purposes of eligibility confirmation or in case of a safety event.
- Agrees to provide the name and verifiable contact information (email and mailing addresses, mobile and land-line phone numbers, as applicable) of at least two persons 22 years or older who reside within a 60-minute drive of the patient's residence. Subject agrees that in the event of a safety concern or event during study participation, research staff is at liberty to contact these individuals if the subject does not respond to contact attempts.
Exclusion Criteria:
- History of serious brain injury or other neurologic disorder.
- Poorly managed general medical condition.
- Pregnant or breast feeding.
- Implanted device in the head or neck.
- MRI intolerance or contraindication.
- Brain stimulation treatment such as ECT, TMS, or VNS (past month).
- Recent change in antidepressant treatments (past month).
- 8. Moderate-High Risk of Suicide according to the Columbia - Suicide Severity Rating Scale (C-SSRS) Screen Version - Recent (answers YES to Question 3 and NO to Question 6 (Moderate risk) or YES to Question 4, 5, or 6 (High risk)) and/or in the clinical judgement of the PI or a study psychiatrist
- Suicidal behavior (past year).
- Serious suicide attempt 33 (lifetime).
- Moderate-to-severe substance use disorder (MINI, past 3 months).
- Obsessive compulsive disorder, primary diagnosis (MINI, past month).
- Posttraumatic stress disorder, primary diagnosis (MINI, past month).
- Bipolar-spectrum disorder (MINI, lifetime).
- Schizophrenia-spectrum disorder (MINI, lifetime).
- Neurocognitive disorder (DSM-5, past year).
- Severe personality disorder.
- Clinically inappropriate for participation in the study as determined by the study team.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Scienza basilare
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione incrociata
- Mascheramento: Triplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Group 1: SCC-ALIC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the subgenual cingulate cortex (SCC) at the first stimulation visit, then LTFUS is delivered to the anterior limb of the internal capsule (ALIC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
|
Sperimentale: Group 2: ALIC-SCC
Low-intensity transcranial focused ultrasound stimulation (LTFUS) is delivered to the anterior limb of the internal capsule (ALIC) at the first stimulation visit, then LTFUS is delivered to the subgenual cingulate cortex (SCC) at the second stimulation visit. |
Low-intensity transcranial focused ultrasound delivered to subgenual cingulate cortex Low-intensity transcranial focused ultrasound delivered to anterior limb of internal capsule |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Modulation of SCC activity during SCC stimulation
Lasso di tempo: Days 14, 21, 28
|
Functional MRI is used to quantify modulation of SCC activity during SCC stimulation |
Days 14, 21, 28
|
|
Modulation of SCC activity during ALIC stimulation
Lasso di tempo: Days 14, 21
|
Functional MRI is used to quantify modulation of SCC activity during ALIC stimulation |
Days 14, 21
|
|
Study dropout
Lasso di tempo: From enrollment to the end of participation at 7 weeks
|
Dropout or withdrawal due to stimulation-related adverse effects |
From enrollment to the end of participation at 7 weeks
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
PANAS-X
Lasso di tempo: Immediately before and after each LTFUS on Days 14, 21, 28
|
Positive and Negative Affect Schedule, Expanded Form |
Immediately before and after each LTFUS on Days 14, 21, 28
|
|
MADRS
Lasso di tempo: Days 14, 21, 28, 35, 49
|
Montgomery-Asberg Depression Rating Scale |
Days 14, 21, 28, 35, 49
|
|
HDRS-6
Lasso di tempo: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
6-item Hamilton Depression Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
IDS-SR
Lasso di tempo: Days 0, 14, 21, 28, 35, 49
|
Inventory of Depressive Symptomatology, Self-Rated |
Days 0, 14, 21, 28, 35, 49
|
|
GAD-7
Lasso di tempo: Days 0, 14, 21, 28, 35, 49
|
7-item Generalized Anxiety Disorder Scale |
Days 0, 14, 21, 28, 35, 49
|
|
YMRS
Lasso di tempo: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Young Mania Rating Scale |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
C-SSRS
Lasso di tempo: Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
Columbia Suicide Severity Rating Scale, Screen Version |
Days 0, 14, 15, 21, 22, 28, 29, 35, 49
|
|
GASE
Lasso di tempo: Days 15, 22, 29
|
Generic Assessment of Side Effects scale |
Days 15, 22, 29
|
|
MoCA
Lasso di tempo: Days 14, 15, 49
|
Montreal Cognitive Assessment |
Days 14, 15, 49
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Investigatore principale: Brian J Mickey, University of Utah
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- IRB_00148802R61
- R61MH134943 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .